SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 20, 2013 (May 17, 2013)
THRESHOLD PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
|(Commission File Number)||
170 Harbor Way, Suite 300
South San Francisco, California 94080
(Address of principal executive offices)(Zip Code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 17, 2013, Threshold Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders.
At the annual meeting, there were at least 48,650,947 shares represented to vote either in person or by proxy, or 86.03% of the outstanding shares, which represented a quorum. The final results of voting for each matter submitted to a vote of stockholders at the meeting were as follows:
Proposal 1: Election of Directors.
Bruce C. Cozadd, David R. Hoffmann and George G.C. Parker, Ph.D. were elected as Class III directors for a term of three years. The voting for each director was as follows:
|Bruce C. Cozadd||34,105,147||4,216,247||10,329,553|
|David R. Hoffmann||34,823,166||3,498,228||10,329,553|
|George G.C. Parker, Ph.D.||30,569,583||7,751,811||10,329,553|
Proposal 2: Ratification of Independent Registered Public Accounting Firm.
Ernst & Young LLP was ratified as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2013 with 46,726,546 votes in favor, 227,499 votes against and 1,696,902 abstentions.
Proposal 3: Advisory Vote on Executive Compensation.
The Company’s executive compensation was approved on a non-binding, advisory basis based upon the following votes:
Proposal 4: Advisory Vote on the Frequency of the Advisory Vote on Executive Compensation.
A yearly frequency for an advisory vote on the Company’s executive compensation was approved, on a non-binding, advisory basis based upon the following votes:
|3 Years||2 Years||1 Year||Abstain||Broker Non-Vote|
Proposal 5: Approval of Amendments to Our 2004 Amended and Restated Equity Incentive Plan.
The proposal to amend our 2004 Amended and Restated Equity Incentive Plan to (a) increase the Section 162(m) fiscal year grant limits on existing and new employees in Section 5.2(a) of the 2004 Equity Incentive Plan FROM 202,401 and 303,601 TO 2,000,000 and 3,000,000, respectively, (b) increase the aggregate number of shares of common stock authorized for issuance under the plan from 7,922,804 shares to 8,422,804 shares, (c) increase the automatic annual increase in the number of shares of common stock authorized for issuance under the plan FROM a number of shares equal to the lesser of (i) 5% of the number of the Company’s shares issued and outstanding prior to the preceding December 31, (ii) 1,250,000 shares, or (iii) a number of shares set by our board of directors, TO a number of shares equal to the least of (x) 5% of the number of the Company’s shares issued and outstanding as of the preceding December 31, (y) 1,750,000 shares or (z) a number of shares set by our board of directors, and (d) to extend the term of the 2004 Equity Incentive Plan from ten years ending April 7, 2014 to ten years from the date of our Annual Meeting, or May 17, 2023, was not approved based on the following votes:
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|THRESHOLD PHARMACEUTICALS, INC.|
|By:||/s/ Joel A. Fernandes|
|Joel A. Fernandes|
|Vice President, Finance and Controller|
Date: May 20, 2013